2021
January
Focus on suppressive macrophages may boost effects of PARP inhibitors
January 13, 2021
Even though FDA-approved poly(ADP-ribose) polymerase inhibition (PARPi) can be very effective in BRCA-mutant breast cancer, responses are not durable, prompting a need for combination therapies. To provide a mechanistic basis for considering immunotherapeutic strategies, Mehta et al. used high-dimensional single-cell and multi-omics profiling in patient samples and in mouse models to study changes...